

Diabetes Monitoring for People with Diabetes and Schizophrenia

CBH is committed to ensuring members receive quality care. This measure assesses adults 18 to 64 years of age with schizophrenia and diabetes, who had both an LDL-C test and HbA1c test during the measurement year. People with serious mental illness who are taking an antipsychotic medication and have diabetes should be monitored to prevent worsening of health conditions.

For more information, see the [National Committee for Quality Assurance \(NCQA\) Behavioral Health Resource Center](#).

Best Practices

- ➔ Monitor members with diabetes and schizophrenia at least annually, particularly those who do not have regular contact with a primary care physician (PCP).
 - » LDL-C and HbA1c are indicated for monitoring.
 - » Inform members when labs are due and help members find a lab location close to their homes.
- ➔ Monitoring for diabetes is indicated when:
 - » Medications are initiated, changed, or titrated;
 - » Three to four months after medication is initiated; and
 - » Annually thereafter.
- ➔ Discuss results with members and refer to PCP as appropriate.
- ➔ Collaborate with case management and PCPs on member care strategies. Ensure the results are communicated in a timely fashion to other healthcare providers involved in the care of the member.
- ➔ Perform other recommended monitoring, such as blood pressure, weight, regularly updated medical history, and medical lists.

Schizophrenia Diagnoses Associated with this Measure

- ➔ [F20.0] Paranoid Schizophrenia
- ➔ [F20.1] Disorganized Schizophrenia
- ➔ [F20.2] Catatonic Schizophrenia
- ➔ [F20.3] Undifferentiated Schizophrenia
- ➔ [F20.5] Residual Schizophrenia
- ➔ [F20.81] Schizophreniform Disorder
- ➔ [F20.89] Other Schizophrenia
- ➔ [F20.9] Schizophrenia, Unspecified
- ➔ [F25.0] Schizoaffective Disorder, Bipolar Type
- ➔ [F25.1] Schizoaffective Disorder, Depressive Type
- ➔ [F25.8] Other Schizoaffective Disorders
- ➔ [F25.9] Schizoaffective Disorder, Unspecified

Lab Screenings Associated with this Measure

HbA1c Test

CPT: 83036, 83037

LDL-C Test

CPT: 80061, 83700, 83701, 83704, 83721

Resources

- ➔ [CBH: HEDIS Tip Sheets](#)
- ➔ [CBH: Pharmacy Resources for Members](#)
- ➔ [CBH: Pharmacy Resources for Providers](#)
- ➔ [CBH: Integrated Care Plan Resources for Members](#)
- ➔ [NCQA Supports Medicaid Behavioral Measure Reporting](#)
- ➔ [AHA/ASA Journals: Harmonizing the Metabolic Syndrome](#)
- ➔ [CMS: Measures Inventory Tool](#)
- ➔ [CDC: A1C Test for Diabetes and Prediabetes](#)

Diabetes Monitoring for People with Diabetes and Schizophrenia

Screening for Metabolic Syndrome Components Based on APA Clinical Practice Guideline for the Treatment of Patients with Schizophrenia

Parameter	Suggested Frequency
Metabolic syndrome (currently defined as presence of at least 3 of the following 5 risk factors: elevated waist circumference; elevated triglycerides; reduced HDL-C; elevated blood pressure; and elevated fasting glucose)	Determine if metabolic syndrome criteria are met at 4 months after initiating a new antipsychotic and at least annually thereafter
Vital signs (pulse, blood pressure, temperature)	As clinically indicated
Body weight, height, and Body Mass Index (BMI)	BMI every visit for 6 months and at least quarterly after
Diabetes (screening for diabetes risk factors, fasting blood glucose)	Fasting blood glucose or hemoglobin A1C at 4 months after initiating a new treatment and at least annually after
Hyperlipidemia (lipid panel)	Lipid panel at 4 months after initiating a new antipsychotic medication and at least annually thereafter

Lab Coverage Information

Health Plan	Laboratory Provider
Community Behavioral Health	Atlantic Diagnostic Laboratories Parkway Clinical Laboratories
Jefferson Health Plans	Quest Diagnostics
Keystone First	LabCorp
United Healthcare	LabCorp Quest Diagnostics
Gelsinger	LabCorp Quest Diagnostics Jefferson Health
PA Health and Wellness	LabCorp Quest Diagnostics
UPMC	Quest Diagnostics

Disclaimer: The information contained in this tip sheet is for educational and informational purposes only. The clinical services described in this tip sheet may not be covered for all CBH enrollees. To find out about what services are available to you under the CBH benefit package, please contact CBH Provider Operations at 215-413-3100.